

Paradigm Biopharmaceuticals Ltd

22:27 14 Apr 2019

Paradigm Biopharmaceuticals raising \$77.9 million to fund its pivotal phase 3 OA trial

Paradigm Biopharmaceuticals Ltd (ASX:PAR) has launched a \$77.9 million capital raise to fund its pivotal phase 3 OA clinical trial in the US, EU and Australia.

The funds will also be used to complete the phase 2/3 pivotal clinical trial in MPS.

The offer comprises a \$51.6 million placement to professional, institutional and sophisticated investors across Australia, Asia and the US including some existing shareholders.

Paradigm is also raising \$26.3 million via an underwritten 1 for 8 accelerated non-renounceable entitlement offer to eligible shareholders.

Complete Phase 2/3 MPS (Rare Disease) Pivotal Clinical Trial	A\$7.0m
Complete Phase 3 Osteoarthritis Pivotal Clinical Trial	A\$30.0m
Employ US Based staff x 2	A\$3.0m
Working capital, offer costs, further preclinical studies and IP acquisitions	A\$37.9m
Total use of funds	A\$77.9m

Proposed use of funds

In conjunction with the capital raise, Paradigm has revealed that it has successfully met the primary and secondary endpoints of its phase 2b trial in OA of the knee.

Paradigm will have a cash position of \$82 million post the capital raising which will put the company in a strong negotiating position for commercial transactions.

Placement and entitlement offer

The placement will result in the issue of 34,370,099 shares and the entitlement offer will result in the issue of 17,537,431 shares, at an offer price of \$1.50 per share.

The offer price represents a 21.1% discount to last close on April 10, 2019.


Settlement of the placement and institutional entitlement offer is expected to occur on April 24, 2019 with new shares allotted the trading next day.

The retail entitlement offer is expected to close on May 6, 2019.

Price: 2.85

Market Cap: \$646.84 m

1 Year Share Price Graph



August 2019 February 2020 August 2020

Share Information

Code: PAR

Listing: ASX

52 week High Low
4.5 1.08

Sector: Pharma & Biotech

Website: www.paradigmbiopharma.com

Company Synopsis:

Paradigm Biopharmaceuticals Ltd (ASX:PAR) is listed on the Australian Securities Exchange.

action@proactiveinvestors.com

Release of OA Phase 2B Secondary Endpoints	Pre-market Monday 15 April 2019
Trading Halt extended through	Monday 15 April – Tuesday 16 April 2019
Company resumes trading and completion of Institutional Entitlement Offer announced Record date (as at 7.00pm) for eligibility under the Entitlement Offer	Wednesday, 17 April 2019
Settlement of New Shares issued under the Placement and the Institutional Entitlement Offer Retail Entitlement Offer Opens	Wednesday 24 April 2019
Allotment of New Shares issued under the Placement	Friday, 26 April 2019

Indicative timetable

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Paradigm Biopharmaceuticals Ltd named herein, including the promotion by the Company of Paradigm Biopharmaceuticals Ltd in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).